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Abstract 
Bacteria produce several protein toxins that act inside cells. These toxins bind with high affinity to glycolipid or glycoprotein receptors present 
on the cell surface. Binding is followed by endocytosis and intracellular trafficking inside vesicles. Different toxins enter different intracellular outes, 
but have the common remarkable property of being able to translocate their catalytic subunit across a membrane into the cytosol. Here, a toxin 
modifies a specific target with ensuing cell alterations, necessary for the survival and diffusion strategies of the toxin producing bacterium. 
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1. Iutroduction 
Many pathogenic bacteria produce protein toxins that 
are important or essential virulent factors [l-3]. Bacterial 
protein toxins can be divided in two groups: (a) toxins 
acting at the plasma membrane level, where they inter- 
fere with transmembrane signalling pathways or alter 
membrane permeability; (b) toxins acting inside cells 
where they enzymatically modify a specific cytosolic tar- 
get. This short review will focus on the mechanism of cell 
penetration of this latter group of toxins. 
In several cases the toxin is solely responsible for all 
clinical symptoms of the corresponding disease. Hence, 
understanding the mechanism of cell intoxication leads 
both to the knowledge of the molecular pathogenesis and 
to the discovery of new aspects of cell physiology. In the 
case of bacterial toxins, this basic knowledge has resulted 
in many applications: (a) toxins are powerful tools to 
study cellular functions [l-3]; (b) several toxins are now 
used in the treatment of various tumors after coupling 
to suitable tumor-specific vectors [4]; (c) the botulinum 
neurotoxins are used in the therapy of a series of 
dystonias [5]. 
These toxins are characterized by an overall similar 
structural and functional architecture. They consist of 
two disulfide-linked parts: protomer A is endowed with 
an enzymic activity which is displayed in the cell cytosol, 
while protomer B is responsible for cell binding and 
penetration (Fig. 1). 
The process of cell intoxication has been traditionally 
divided into three steps: binding, penetration and target 
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modification. Recent evidence based mainly on diphthe- 
ria toxin (DT) and Pseudomonas aeruginosa exotoxin A 
(ETA) and on new developments in the study of cell 
membrane trafficking indicate that a three-step model is 
no longer adequate to describe the process. Here, cell 
intoxication is discussed in terms of a four-step process 
composed of binding, internalization, membrane 
translocation and enzymic modification of a cytosolic 
target. 
2. Binding to cells 
The clinically active concentrations of toxins are very 
low [6]. Moreover, some of them are released in a rapidly 
cleared environment such as the gastrointestinal tract. 
Hence, they have to bind rapidly and firmly to the cell 
surface. They do so via two different modes of binding 
and this corresponds to two different toxin structural 
organizations (Fig. 1). 
Oligomeric B toxins are composed of a pentameric 
disc-shaped binding protomer with a small central cavity 
[7-91. Each B subunit of heat-labile Escherichia coli toxin 
(LT), cholera toxin (CLT) and Shiga toxin (ST), contain 
a low affinity binding site for the oligosaccharide of a 
glycolipid molecule [l-3]. These toxins are thought to 
bind to cells via a first interaction with one glycolipid 
molecule, rapidly followed, in the two-dimensional plane 
of the plasma membrane, by encounters with other 
glyocolipid molecules. The final result is a high-affinity 
cell association due to a pentavalent binding. Pertussis 
toxin (PT) acts in the upper respiratory tract and its B 
protomer has the same oligosaccharide binding fold with 
the addition of two lateral projections, that are believed 
to be involved in binding glycoproteins [9]. 
The catalytic domain A has little protein-protein con- 
tacts with B to which is linked via a long cc-helical seg- 
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Fig. 1. Schematic structure of bacterial protein toxins with intracellular targets. These toxins are organized in an active protomer A, endowed with 
catalytic activity, linked via a disulfide bond to a B protomer, responsible for cell binding and penetration. The toxin is synthesized as a single 
polypeptide chain and cleaved at a single site by proteases. Reduction is required to freed the enzymic activity of A. (1) A group of toxins including 
diphtheria toxin, exotoxin A, tetanus and botulinum neurotoxins and the anthrax toxic complex are organized in three domains: A is the enzyme 
part, R is responsible for cell binding and T is involved in the membrane translocation of A (see Fig. 2). (2) Another group of toxins which includes 
cholera toxin, heat-labile toxin, pertussis toxin and the Shiga toxins are characterized by an oligomeric saccharide binding protomer B. The catalytic 
subunit Al is linked via a linker peptide (A2) that extends inside a central pore of oligomer B. There is very little protein-protein contact between 
A and B. The saccharide binding sites (indicated by a star) are located in the lower part of the B oligomer. At variance from the three-domain toxins, 
here it is impossible to identify a membrane translocating domain. 
ment and a segment which penetrates into the central 
hole of the B oligomer. Hence, upon cell binding, the A 
moiety points toward the extracellular medium, dozens 
of Angstroms away from the membrane surface. 
The second type of toxin structure is that of DT and 
ETA [lO,l l] with three distinct domains (Fig. 1). This 
three-domain organization is likely to be shared by teta- 
nus neurotoxin (TeNT) and botulinurn neurotoxins 
(BoNT) [12] and by the antrax complex [13]. The B 
protomer is composed of two parts, endowed with differ- 
ent functions: R, a COOH-terminal receptor binding do- 
main; and T, an amino-terminal domain involved in 
membrane translocation. The A moiety is linked to B via 
an exposed peptide loop and by the interchain disulfide 
bond. 
The cell surface receptor of DT and ETA have been 
recently identified [ 14,151 as a receptor for a heparin-like 
growth factor and the A,-macroglobulin receptor, re- 
spectively. Acidic lipids are proposed to play a minor 
role in the binding but a significant one in membrane 
translocation (see below). 
3. Internalization 
While binding does not depend on temperature, the 
toxin-receptor complex is internalized inside membrane 
vesicles only at permissive temperatures (i.e. above 
1O’C) (Fig. 2). This stage is very relevant in the immu- 
notherapy of tetanus or botulism, because, after internal- 
ization, the toxin is no longer neutralized by anti-toxin 
antibodies. The different temperature dependence and 
accessibility to external igands operationally distinguish 
the two initial steps of cell intoxication. 
Endocytosis may take place via coated vesicles, as it 
is the case for DT and ETA, or via non-coated vesicles, 
as found for CLT and TeNT [l&19]. Only partial infor- 
mation is available on the intracellular routing of these 
toxins. Morphological studies indicate that ST and ETA 
undergo a retrograde transport to the TGN, Golgi and 
ER [20]. The presence in ETA of a sequence similar to 
the ER-retention sequence may be involved in the recy- 
cling of this toxin inside ER [21]. CLT and LT bind to 
the apical membrane of polarized epithelial cells of the 
intestine and display their activity versus the adenylate 
cyclase localized on the basolateral membrane [22]. 
There is evidence that CLT is transported to the TGN 
[23]. The intracellular membrane compartment from 
where they enter the cytosol is not known for any of these 
toxins. 
DT is the most intensively studied of these toxins and 
the one for which more information is available. After 
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Fig. 2. Schematic picture of the four steps of the mechanism of cell intoxication with A-B type bacterial protein toxins. This process can be sub-divided 
into four different steps, characterized by a different opological orientation of the toxin with respect o the cell. (1) Cell binding occurs via interaction 
of protomer B with a lipid and/or protein component of the cell surface. (2) Binding is followed by internalization via endocytosis and intracellular 
routing. (3) In order to reach the cytosol, the catalytic A subunit of the toxin has to cross the vesicle membrane, aprocess assisted by the T domain 
in the three domain toxins. (4) The enzymatic A subunit performs its catalytic activity toward a specific cytosolic target with ensuing cell intoxication. 
few minutes upon warming a cell with DT bound onto 
the surface, DT is present inside early endosomes. About 
one-third of the internalized DT adopts a state compe- 
tent to membrane translocation and release of A in the 
cytosol[24]. The remaining two-thirds are unable to per- 
form such a step (discussed in the next section) and they 
are degraded inside late endosomes and lysosomes in a 
process blocked by bafilomycin Al, which inhibits the 
vacuolar ATPase proton pump and the vesicular trans- 
port from early to late endosomes [24-261. From intoxi- 
cated cells, Beaumelle et al. [27] were able to isolate 
endosomal fractions containing DT. There is indirect 
evidence that other three-domain toxins such as TeNT 
and BoNT and the antrax edema (EF) and lethal (LF) 
factors enter the cell cytosol via an acidic intracellular 
compartments since cell intoxication is prevented by 
agents that quench intracellular pH gradients [28-301. 
4. Membrane translocation 
4. I. Three-domain toxins 
Since the targets of these toxins are located in the 
cytosol (or are membrane-bound and face the cytosol), 
at least the catalytic A subunit of the toxin has to cross 
the lipid bilayer (Fig. 2). This is the most obscure passage 
of the entire intoxication process. Membrane transloca- 
tion is clearly distinct from internalization because it is 
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now known that only a minor proportion of the internal- 
ized toxin molecules is actually able to translocate the A 
moiety in the cytosol. In the case of ETA and DT, it was 
estimated that < 5% and < 35%, respectively, of internal- 
ized toxin enters the cytosol [24,31]. Moreover, after in- 
ternalization, toxins appear to be able to participate in 
elaborated vesicular trafficking processes [20,32]. Per- 
haps the most striking example is provided by the intra- 
neuronal routing of TeNT. Both TeNT and BoNT bind 
to the presynaptic membrane of motorneurons and are 
internalized inside vesicles at the neuromuscular junction 
(NMJ). While BoNT enter the cytosol of the NMJ syn- 
apse, TeNT remains inside vesicles that move retroaxon- 
ally to the motorneuron cell body and is discharged in 
the intersynaptic space with inhibitory interneurons of 
the spinal cord. Here, TeNT is taken up and enters the 
interneuron cytosol where it blocks release of neuro- 
transmitter [12,32]. The opposite behaviour of TeNT and 
BoNT at the NMJ clearly indicates that internalization 
is not necessarily followed by membrane translocation in 
the cytosol. Moreover, Beaumelle et al. [27] have physi- 
cally separated internalization from membrane translo- 
cation. From cells that had internalized DT, they have 
isolated DT-containing endosomal fractions and showed 
that subunit A could be induced to translocated from the 
endosomal umen to the external medium upon incuba- 
tion with ATP, thus providing further evidence to the 
fundamental role of low pH. 
The three-domain toxins appear to cross membranes 
with a mechanism different from the oligomeric B toxins, 
and hence they will be treated here separately. A com- 
mon property of the three-domain toxins (DT, TeNT, 
BoNT and antrax), but not of the oligomeric B toxins, 
is their ability to form at low pH ion channels in planar 
lipid bilayers; this property is associated to the T domain 
[33-391. In the case of DT and antrax protective antigen, 
a monovalent ion channel was shown to form also in 
living cells [40-43]. This toxin channel has been consid- 
ered an evidence in favour of the ‘tunnel model’ for the 
membrane translocation of the catalytic subunit, first 
proposed by Boquet et al. [44]. It is suggested that the 
acid endosomal pH triggers a conformational change of 
the B subunit that enables it to penetrate the lipid bilayer 
and form a transmembrane channel large enough to ac- 
comodate the A chain in an unfolded form. The catalytic 
subunit crosses the membrane, protected form contact 
with lipids, refolds in the neutral pH of the cytosol and 
leaves behind the protomer B ion channel, after reduc- 
tion of the A-B disulfide bond. A large number of studies 
have documented the conformational change of several 
toxins induced by low pH and the membrane insertion 
of the hydrophobic ‘acid’ form [45547]. 
Although there are differences among the ion channels 
formed by the various toxins, the main general properties 
are summarized in Table 1 and compared with those of 
the protein conducting channels of the endoplasmic 
reticulum and E. coli bacterial membrane [48,49]. This 
comparison indicates that a protein with bulky hydro- 
phobic lateral residues is unlikely to pass through such 
a toxin channel. The ‘tunnel model’ is also unable to 
account for the fact that at low pH the catalytic A sub- 
unit does enter in contact with the fatty acid chains of 
phospholipids [Xl-521. 
An alternative view suggests that the toxin channels 
detected in planar lipid bilayers and cell plasma mem- 
branes are actually different from the physical entities 
that translocate the A chain across the membrane. In 
other words, the toxin channel is a left-over of step 3: it 
was involved in the process, but has afterwards changed 
its structural and electrical properties [45]. This ‘cleft 
model’ suggests that the acid endosomal pH triggers a 
concerted conformational change of the B and the A 
subunits, that become hydrophobic and penetrate the 
lipid bilayer. B forms a hydrophilic cleft that drives the 
insertion of A with its hydrophilic segments interacting 
with the B cleft and the hydrophobic segments exposed 
to lipids, thus accomodating bulky aromatic lateral 
chains. A proper matching of hydrophobic and hydro- 
philic protein-lipid and protein-protein interactions is 
needed to reduce the energetic cost of the translocation 
process. It is possible that the A protomer has a net 
positive charge at low pH. Due to the high energetic ost 
of driving charged groups across the hydrophobic core 
of the lipid bilayer, membrane insertion and transloca- 
tion would be facilitated by formation of ionic couples 
with negatively-charged phospholipid head groups. This 
proposal emphasizes the role of non-bilayer lipidic con- 
figurations [53], though direct evidence for such struc- 
tures during the membrane translocation of toxins is 
lacking. 
Available data are insufficient to draw a picture of 
protomer B folding in the membrane for any of the 
known toxins. Most efforts are concentrated on DT and 
the protein segments of DT embedded in the lipid bilayer 
at low pH are being identified [54,55]. Parker and Pattus 
[47] have noticed that membrane inserting toxins possess 
a hairpin of hydrophobic helices shielded by the other 
helices of their T domain. They have suggested that 
acidic pH triggers the exposure of such a hydrophobic 
Table 1 
Comparison of the properties of toxin ion channels and protein con- 
ducting channels of endoplasmic reticulum and bacterial membrane 
Propery channel Toxin channels Protein-conducting 
Conductance 5-43 ps 220 ps 
Ion selectivity X’ non-selective 
Size of permanenent ion < glucosamine < gluconate 
pH dependence 4-6 n.d. 
Voltage gating + - 
Voltage dependence of + - 
conductance 
References in the text. 
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hairpin, which into the and forms 
nucleus around the membrane de- 
vices these toxins organized. 
The that chain can escape liposomes 
once is returned neutrality [51], experi- 
mental for the of the 
ble ‘neutral’ upon exposure the neutral 
pH. Chain can leave membrane only reduc- 
tion the interchain bond. For this is 
rate-limiting step the entire intoxication process 
After chain has left membrane, the 
of the cleft embedded the lipid 
come closer minimize the of hydrophilic 
tein surface to the chains of 
This leaves a transmembrane of hydro- 
residues which a flat-shaped chan- 
nel reduced size low conductance. the ‘tunnel’ 
the channel translocates chain and the 
cation channel the same and for- 
of the is a for membrane 
of chain In the model, the 
channel is to the that has the 
translocation chain A, has no the same 
and properties. 
Oligomeric B toxins 
The oligomeric B toxins also act on cytosolic targets 
and face the problem of the membrane translocation of 
chain A. Low pH does not appear to induce a conforma- 
tional change and membrane penetration of these toxins. 
Membrane photolabelling studies [56] and the 3D struc- 
ture of oligomeric B toxins [7-9,57,58] are only compat- 
ible with a mode of binding with the Al subunit pointing 
out of the cell surface. 
It has been suggested that, upon membrane binding, 
the B oligomer penetrates in the bilayer and that Al 
crosses the membrane inside a tunnel made by the B 
oligomer [59,60]. However, membrane photolabelling 
experiments how no penetration of B into the bilayer 
[56]. In addition, the central pore of oligomer B is too 
small, particularly in the case of PT [7-91. Membrane 
photolabelling and image reconstruction of two-dimen- 
sional crystals also showed no lipid interaction of Al. It 
contacts lipids only after reduction of the Al-A2 disul- 
fide bridge [56]. On this basis, it was proposed that the 
trigger of the membrane insertion of Al is the reduction 
of this interchain S-S bond, that releases a hydrophobic, 
water-insoluble Al chain [56]. Hence, it appears that 
GM1 binding concentrates the toxin on the membrane 
in such a way that, as soon as the disulfide bridge is 
reduced, Al ‘rolls over’ oligomer B and inserts into the 
membrane. This is at variance with the mechanism of 
membrane penetration of the three-domain toxins, where 
protomer B plays an active role in the insertion of the 
catalytic subunit. The B oligomer merely places Al near 
the membrane surface to maximize its insertion into the 
lipid bilayer. Also for these toxins, neither the chemical 
nature of the reducing agent nor the intracellular posi- 
tion at which this step takes place are known. 
After membrane insertion, the surface distribution of 
the various amino acid residues is expected to drive the 
correct orientation of Al with respect to the cytosolic 
substrate NAD. Vesicles carrying CLT or LT have 
finally to fuse with the basolateral membrane of the 
entherocyte cell to allow contact with their target, the 
adenylate cyclase complex [58]. Conversely, the A chain 
of ST acts on the 60 S ribosomal particle and hence has 
to leave the vesicle and dissolve in the cytosol similarly 
to the A subunits of DT and ETA. 
5. Target modification 
This fourth step is the final goal of the overall intoxi- 
cation proces. Table 2 lists the enzymatic activities dis- 
played inside cells by bacterial toxins. The largest group 
is that of the ADP-ribosyltransferases: they bind cy- 
tosolic NAD’ and transfer the ADP-ribose moiety to a 
variety of cytosolic toxin-specific targets. DT and ETA 
modify specifically elongation factor 2 and block protein 
synthesis with consequent cell death [59,60]. It has been 
estimated that a single molecule of A is sufficient to kill 
a cell [62]. In contrast, cells intoxicated by other ADP- 
ribosyltransferases such as CLT, LT, and PT do not die, 
but have an altered physiology due to a large increase in 
c-AMP levels because these toxins specifically modify 
G-proteins involved in the control of adenylate cyclase 
[63]. Cellular effects differ as a function of the type of 
intoxicated cell. 
Other ADP-ribosyltransferases produced by several 
Clostridium spp. direct their action on actin polimeriza- 
tion. The C-2 toxin specifically modifies G-actin, pre- 
venting formation of actin filaments [64], while the C-3 
enzyme ADP-ribosylates Rho, a protein involved in the 
control of actin polymerization [65]. As a result, all phe- 
nomena depending on a functional contractile apparatus 
are altered and the cell may eventually die. 
The edema factor of the entrax toxin complex (EF) is 
a cahnodulin-dependent adenylate cyclase that causes a 
rapid rise of c-AMP and cell rounding [13]. Also 
Bordetella pertussis produces an adenylate cyclase toxin 
(BP-ADC) [66]. The increase of the cellular level c-AMP 
produced by these two toxins is only transient, because 
they are rapidly degraded by cellular proteases [13,66]. 
Yet another kind of activity is displayed by the Shiga 
toxins (STs). Like several plant toxins named RIPS [67], 
STs remove a single adenine residue from the 28s ribo- 
somal RNA [68]. This impairs the function of the 60s 
ribosomal subunit and blocks protein synthesis [69]. The 
final result is the same as that caused by DT and ETA: 
cell and tissue necrosis [68]. 
The most recent addition to the enzyme activities of 
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Table 2 
Enxyrne activities and cytosolic targets of bacterial protein toxins with 
intracellular targets 
Acknowledgements: We thank P. Boquet for critical reading of the 
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Toxin Activity Target Effect 
DT ADP-ribosyl- EF-2 Blockade of protein synthesis 
transferase and cell death 
ETA ADP-ribosyl- EF-2 Blockade of protein synthesis 
transferase and cell death 
CLT ADP-ribosyl- G, Increase c-AMP (alteration of 
transferase permeability) 
LT ADP-ribosyl- G. Increase c-AMP (alteration of 
transferase permeability) 
PT ADP-ribosyl- Gi, Gt Increase c-AMP (various 
transferase effects) 
c2 ADP-ribosyl- Actin Cell rounding and detachment 
transferase 
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